Articles
 

Report of Six Cases of Chediak-Higashi Syndrome with Regard to Clinical and Laboratory Findings

Abstract

Chediak - Higashi Syndrome (CHS) is a rare, primary Immunodeficiency disorder with an autosomal recessive (AR) inheritance and characterized by re¬current infection, partial occulocutaneous albinism and an accelerated phase.
In this report we describe clinical and laboratory findings from 6 CHS pa¬tients.
Clinical and laboratory information of six patients who were referred to our center during the last 20 years (from 1983 - 2003) were reviewed.
Onset age of disease was between 3 months to 10 years. All patients had history of consanguineous parents and two patients were siblings. All patients had oculocutaneous albinism, nystagmus, recurrent infections which included upper and lower respiratory tract (U&LRT) infections, stomatitis, thrush, and skin ab¬scesses and hepatitis. In laboratory findings, all patients had neutropenia and normal immunoglobulins and normal CD3, CD4, CD8and CD 19 lymphocyte by flowcytometry and three of the four patients had chemotatic defect. Five patients certainly had giant granule in bone marrow neutrophil and in one patient it was equiovocal. Three patients had an accelerated phase, and for one patient bone marrow transplantation was done that was tolerated well and had been well after 7 years.
We emphasize the need for early diagnosis on basis of characteristic facies and diagnostic laboratory examinations and early bone marrow transplantation (BMT) in patients.
Files
IssueVol 2, No 4 (2003) QRcode
SectionArticles
Keywords
Chediak-Higashi Syndrome

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Abolhasan Farhoudi, Zahra Chavoshzadeh, Zahra Pourpak, Mina Izadyar, Mohammad Gharagozlou, Masoud Movahedi, Asghar Aghamohamadi, Bahram Mir saeid Ghazi, Mostafa Moin, Nima Rezaei. Report of Six Cases of Chediak-Higashi Syndrome with Regard to Clinical and Laboratory Findings. Iran J Allergy Asthma Immunol. 1;2(4):189-192.